Tracing the path of Parkinson's disease proteins

August 4, 2017
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

As neurodegenerative disorders such as Parkinson's and Alzheimer's disease progress, misfolded proteins clump together in neurons, recruiting normal proteins in the cell to also misfold and aggregate. Cells in which this occurs degenerate and eventually die. Being able to keep an eye on the whereabouts of these corrupted proteins is key to unraveling these diseases and developing cures.

A team of researchers has now developed a set of tools to observe, monitor and quantify how misfolded proteins associated with Parkinson's enter in laboratory cultures and what happens to them once they're inside. The results will be published in the Aug. 11 issue of the Journal of Biological Chemistry.

Alpha-synuclein is a protein found in all neurons, where it is thought to be involved in regulating neurotransmitter release. Incorrectly folded sticks together, forming fibrous deposits called . These are the main components of Lewy bodies, the masses seen in the neurons of Parkinson's patients.

In 2011, Virginia Lee's group at the Center for Neurodegenerative Disease Research at the University of Pennsylvania showed that if lab-produced alpha-synuclein fibrils were added to neurons growing in a dish, the neurons would develop Lewy bodies and display other symptoms of neurodegeneration. This study and others hinted that misfolded alpha-synuclein could spread from cell to cell, rather than forming anew in every individual cell. However, there was no way to directly observe the initial steps of alpha-synuclein fibrils entering .

"Our understanding of neurodegenerative disease—or even the normal function of the healthy brain, for that matter - is limited by the techniques we currently have at our disposal," said Richard Karpowicz Jr., a postdoc in Lee's lab who led the new study.

Karpowicz devised a simple but sensitive method to visualize alpha-synuclein fibrils entering cells. First, he cultured neurons and synthesized alpha-synuclein fibrils tagged with fluorescent proteins. Next, he put the cells and fluorescent fibrils in a dish together. Then he added a dye, called trypan blue, that turns off fluorescent tags. Importantly, this dye cannot pass through intact cell membranes, which means it cannot turn off tags that are already inside cells. Once he added the dye, the glowing fibrils outside of cells turned off, but the ones that had already entered the cell continued to glow, allowing him to visualize and count the internalized fibrils.

Furthermore, in collaboration with E. James Petersson's research group in the Department of Chemistry at the University of Pennsylvania, the researchers also developed fibrils labeled with long-lasting fluorescent tags that were either sensitive or insensitive to acidity. Based on whether the fluorescence was visible, the researchers could determine when the fibrils entered acidic compartments in the cell, allowing them to deduce the cellular processes that acted on the fibrils.

Using these methods, the team was able to gain several insights into the fate of fibrils entering cells. They found that fibrils were actively engulfed by the cell membrane and transported to the lysosomes, the cell's waste disposal compartment, where most of the fibrils remained for days. "It's amazing how much the cell is able to sequester," Karpowicz said. But despite the cells' best efforts, some fibrils found their way out of the lysosomes and induced aggregation.

When the researchers added chloroquine to the cells to inhibit lysosomal activity, more and more of the native alpha-synuclein was recruited to form aggregates. Lysosomal dysfunction is often observed in patients with neurodegenerative diseases. "We know that some of [the pathological proteins], somehow, get out of the lysosomes," Lee said. "But we don't know how that happens."

But being able to accurately quantify the amount of taken up will allow researchers to rapidly screen potential pharmacological compounds that could one day be used to stop the spread of the corrupted proteins in a patient. "Once you can look at [fibril] uptake into the cell, and quantify how much is inside the cell, then you can add small molecules to it to see if you can reduce uptake," Lee said. "It's really a simple assay and doesn't take very long." Karpowicz added that looking at genetic variation in these uptake pathways could provide hints as to why some people are more susceptible to the disease than others.

Explore further: Tunneling nanotubes between neurons enable the spread of Parkinson's disease via lysosomes

More information: Richard J. Karpowicz et al, Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies, Journal of Biological Chemistry (2017). DOI: 10.1074/jbc.M117.780296

Related Stories

Tunneling nanotubes between neurons enable the spread of Parkinson's disease via lysosomes

August 22, 2016
Scientists from the Institut Pasteur have demonstrated the role of lysosomal vesicles in transporting α-synuclein aggregates, responsible for Parkinson's and other neurodegenerative diseases, between neurons. These proteins ...

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

Researchers identify when Parkinson's proteins become toxic to brain cells

March 14, 2016
Researchers have used a non-invasive method of observing how the process leading to Parkinson's disease takes place at the nanoscale, and identified the point in the process at which proteins in the brain become toxic, eventually ...

SUMO defeats protein aggregates that typify Parkinson's disease

July 11, 2011
A small protein called SUMO might prevent the protein aggregations that typify Parkinson's disease (PD), according to a new study in the July 11, 2011, issue of The Journal of Cell Biology.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

A better model for Parkinson's disease

February 1, 2016
Scientists at EPFL solve a longstanding problem with modeling Parkinson's disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.

Recommended for you

Data, technology drive new approaches to Parkinson's care

October 23, 2017
Complex, multi-system diseases like Parkinson's have long posed challenges to both scientists and physicians. University of Rochester Medical Center (URMC) researchers are now reaching for new tools, such as algorithms, ...

Investigating the most common genetic contributor to Parkinson's disease

October 19, 2017
LRRK2 gene mutations are the most common genetic cause of Parkinson's disease (PD), but the normal physiological role of this gene in the brain remains unclear. In a paper published in Neuron, Brigham and Women's Hospital ...

Scientists solve 3-D structure of key defense protein against Parkinson's disease

October 5, 2017
Scientists at the University of Dundee have identified the structure of a key enzyme that protects the brain against Parkinson's disease.

Novel protein interactions explain memory deficits in Parkinson's disease

September 26, 2017
A study published in the journal Nature Neuroscience describes the identification of a novel molecular pathway that can constitute a therapeutic target for cognitive defects in Parkinson's disease. The study showed that abnormal ...

Psychosis in Parkinson's dementia—new treatment provides hope

September 25, 2017
New research involving King's College London and the University of Exeter has highlighted the benefits of a promising new treatment which could relieve psychosis in thousands of people with dementia related to Parkinson's ...

Bicycling 'overloads' movement networks with Parkinson's

September 23, 2017
(HealthDay)—Bicycling suppresses abnormal beta synchrony in the Parkinsonian basal ganglia, according to a study published online Sept. 11 in the Annals of Neurology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.